Eribulin Mesylate

Phase 1Active

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Liposarcoma

Conditions

Liposarcoma, Malignant Abdominal Neoplasm, Malignant Retroperitoneal Neoplasm, Malignant Scrotal Neoplasm, Malignant Solid Neoplasm, Malignant Spermatic Cord Neoplasm

Trial Timeline

Mar 19, 2018 → Apr 14, 2033

NCT ID

NCT03361436

About Eribulin Mesylate

Eribulin Mesylate is a phase 1 stage product being developed by Eisai for Liposarcoma. The current trial status is active. This product is registered under clinical trial identifier NCT03361436. Target conditions include Liposarcoma, Malignant Abdominal Neoplasm, Malignant Retroperitoneal Neoplasm.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (19)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03441360	Phase 2	Completed	Apr 17, 2018	Jan 21, 2022	Relapsed/Refractory Rhabdomyosarcoma
NCT03583944	Approved	Completed	Mar 28, 2018	Jun 28, 2019	Breast Neoplasms
NCT03361436	Phase 1	Active	Mar 19, 2018	Apr 14, 2033	Liposarcoma
NCT03437083	Pre-clinical	Completed	Jan 25, 2018	Jun 30, 2018	Locally Advanced or Metastatic Breast Cancer
NCT03058406	Pre-clinical	Completed	Mar 1, 2016	Nov 4, 2018	Sarcoma, Soft Tissue
NCT02481050	Phase 2	Completed	Jun 16, 2015	Sep 5, 2017	Breast Cancer
NCT02338037	Phase 1	Completed	May 19, 2015	Mar 15, 2024	Metastatic Malignant Neoplasm in the Adult Brain
NCT02171260	Phase 1	Completed	Jul 31, 2014	Jan 28, 2016	Pediatrics
NCT03245112	Pre-clinical	UNKNOWN	Mar 3, 2014	Dec 31, 2017	Metastatic Breast Cancer
NCT01961544	Approved	Completed	Jun 1, 2013	Jul 1, 2015	Breast Neoplasms
NCT01458249	Phase 2	Completed	Nov 1, 2011	Feb 1, 2016	Soft Tissue Sarcoma
NCT01463891	Pre-clinical	Completed	Jul 19, 2011	Nov 27, 2013	Inoperable or Recurrent Breast Cancer
NCT01328249	Phase 2	Completed	Mar 3, 2011	Oct 19, 2017	HER2-normal
NCT01240421	Pre-clinical	Completed	Mar 1, 2011	Nov 1, 2014	Metastatic Breast Cancer
NCT01268150	Phase 2	Completed	Feb 1, 2011	Aug 1, 2013	Locally Recurrent
NCT01269346	Phase 2	Completed	Dec 1, 2010	May 1, 2016	Breast Cancer
NCT01142661	Pre-clinical	Completed	Aug 1, 2010	—	Breast Cancer
NCT01106248	Phase 1	Completed	Mar 1, 2009	—	Advanced Solid Tumor
NCT00965523	Phase 2	Completed	Jan 1, 2008	Jan 1, 2011	Breast Cancer

Competing Products

12 competing products in Liposarcoma

See all competitors

Product	Company	Stage	Hype Score
Abemaciclib + Placebo	Eli Lilly	Phase 3	77
efatutazone	Daiichi Sankyo	Phase 2	52
Trabectedin + Dexamethasone	Johnson & Johnson	Phase 2	52
Yondelis + Yondelis + Dexamethasone + Dexamethasone	Johnson & Johnson	Phase 2	52
HDM201 + LEE011	Novartis	Phase 1	33
pazopanib	Novartis	Phase 2	52
PF-07220060 + Midazolam	Pfizer	Phase 2	51
Sunitinib Malate (SU011248)	Pfizer	Phase 2	51
Cabazitaxel	Sanofi	Phase 2	51
INCMGA00012 + Palbociclib	Incyte	Phase 2	49
Selinexor + Placebo	Karyopharm Therapeutics	Phase 2/3	57
Selinexor + Ixazomib	Karyopharm Therapeutics	Phase 1	25

Other Products from Eisai

MecobalaminApproved

MonteplaseApproved

E2020 + PlaceboApproved

Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved

DonepezilApproved